GLP-1: Buy the hype, but don’t be fooled by it
Insights - In a prior note, we shared how weight-loss drugs might impact obesity related markets. The hype craze has pushed additional data that is now being blown … Continue Reading
Read nowBiotech has roared back and seen a strong start to the new year. Since November, in less than 3 months,...
Read NowBristol Myers Squibb announced the acquisition of Karuna (KRTX) for $14B to add a first-in-class schizophrenia drug and neuroscience pipeline....
Read NowInsights - In a prior note, we shared how weight-loss drugs might impact obesity related markets. The hype craze has pushed additional data that is now being blown … Continue Reading
Read nowTranscripts - Larry Biegelsen Good afternoon. I’m Larry Biegelsen, the medical device analyst at Wells Fargo. And it’s my pleasure to host this session with DexCom. With … Continue Reading
Read nowTranscripts - Operator Good day, ladies and gentlemen, and thank you for joining CymaBay’s Phase III RESPONSE trial top line results conference call. [Operator Instructions] Please be … Continue Reading
Read nowTranscripts - Operator Good morning, everyone. Thank you for standing by, and welcome to the Corvus Pharmaceuticals Conference Call. [Operator Instructions]. It is now my pleasure to … Continue Reading
Read nowTranscripts - Operator Good morning. My name is Rob, and I will be your conference operator today. At this time, I would like to welcome everyone to … Continue Reading
Read nowTranscripts - Operator Good morning, everyone, and thank you for joining the Zevra Therapeutics Corporate Update Call to announce the acquisition of Acer Therapeutics. [Operator Instructions] Today’s … Continue Reading
Read nowInsights - GLP-1, initially touted as a therapy for diabetes, have proven successful for weight loss, CV event reduction, and with beneficial effects in HFpEF. Weight is … Continue Reading
Read now